Best Life Sciences Companies in Santa Clara, United States
The 70 best Life Sciences companies in Santa Clara, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cardival Medical.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Santa Clara
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cardival Medical Developer of a device for vascular access management | $169M | 71 mo ago | 158 158 → 241 (+53%) | — | Acquired | — | — | 5 launchs |
| 2 | Benvenue Medical Online slot gaming platform offering diverse games and trusted service | $149M | 125 mo ago | 24 | — | Acqui-Hired | — | 135 patents Minimally invasive spinal interbody fusion devices and graft delivery systems. | — |
| 3 | Shockwave Medical Developer of cardiovascular balloon dilation catheters | $148M | 87 mo ago | 571 | Doug Godshall CEO & President | Acquired | Top 5M | 463 patents Intravascular shockwave lithotripsy catheters for calcified plaque and thrombus removal | 2 launchs |
| 4 | NeuSpera Medical Miniaturized neurostimulation devices | $125M | 23 mo ago | 39 | — | Series D | — | — | — |
| 5 | XenoPort Provider of biopharmaceutical products for neurological disorders and pain management | $101M | 163 mo ago | 156 | — | Acquired | — | 722 patents Sustained‑release oral formulations of fumarate‑based pharmaceutical compounds | — |
| 6 | OptiMedica Developer of medical devices to treat ocular diseases | $95M | 163 mo ago | 60 | Paweł Nessel CEO | Acquired | — | 600 patents Laser ophthalmic surgery devices and patient interface technologies. | — |
| 7 | Shape Memory Medical Developer of embolization devices based on Shape Memory Polymer material | $57M | 14 mo ago | 37 37 → 46 (+24%) | Edward Ruppel CEO & President | Series C | Top 50M | — | — |
| 8 | Cyagen Contract research organization for cell culture product and animal model manufacturer | $41M | 75 mo ago | 900 | — | Series B | Top 5M | — | — |
| 9 | Ilypsa Develops phosphate and potassium binder compounds to treat chronic kidney diseases | $36M | 251 mo ago | 79 | — | Acquired | — | 184 patents Pharmaceutical sodium-binding polymer compositions for drug delivery and therapeutic kits | — |
| 10 | Bacchus Vascular Devices for treatment of vascular disease | $32M | 230 mo ago | — | Gerhard Burbach CEO | Acqui-Hired | — | — | — |
| 11 | Armetheon Small molecule drugs for cardiovascular disorders | $31M | 136 mo ago | 17 | — | Series B | — | 37 patents Novel pharmaceutical compounds and formulations for cardiac arrhythmia, atrial fibrillation, and coagulation disorders | — |
| 12 | NextBio NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and… | $28M | 191 mo ago | 51 | — | Acqui-Hired | — | 24 patents Bioinformatics platforms for sequence data management, analysis, and scientific knowledge integration. | — |
| 13 | Rebus Biosystems Developer of an imaging system for the analysis of genes in a single cell | $20M | 67 mo ago | 15 | Ron Cook Co-Founder | Series B | — | 9 patents High‑resolution structured illumination optical imaging for cellular and particle analysis | — |
| 14 | SpineAlign Medical Design and manufactures medical devices for spine disorders | $16M | 185 mo ago | 1 | Paul Chirico Chairman & Founder | Series A | — | — | — |
| 15 | EchoPixel Cloud-based 3D medical visualization software for professionals | $13M | 110 mo ago | 12 | Sergio Aguirre Founder & Co-CEO | Series A | Top 50M | 29 patents 3D medical imaging annotation and glasses‑free motion tracking for interventional cardiology | — |
| 16 | Agilent Developer of diversified instruments for scientific and laboratory management | $10M | 30 mo ago | 5,968 | Mike McMullen CEO and President | Public | Top 500k | 9,559 patents Advanced analytical and fluidic instrumentation for mass spectrometry and bioassay automation. | 2 launchs |
| 17 | Invenio Imaging Provider of a tissue imagine software and hardware solution for research diagnosis | $8M | 39 mo ago | 13 | Jay Trautman Co-Founder | Series A | — | 26 patents Intraoperative optical and Raman imaging for real-time tissue diagnostics and cytology analysis. | — |
| 18 | Primity Bio Global CRO advancing precision medicine with biomarker platforms and laboratory services | $7M | 113 mo ago | 12 | Peter Krutzik Founder & CEO | Acquired | — | — | — |
| 19 | Lightspeed Genomics Using proprietary optical imaging technology to develop DNA sequencing platform. | $5M | 165 mo ago | — | Josh Ryu President & CEO | Acquired | — | 22 patents Patterned optical excitation for high‑density biomolecule arrays and sequencing | — |
| 20 | Expert Intelligence AI-powered solutions to enhance laboratory workflows | $5M | 4 mo ago | — | Lalin Theverapperuma Founder & CEO | Seed | Top 50M | — | — |
| 21 | Regencor Developer of therapeutic solutions & drugs for cardiac regeneration | $4M | 94 mo ago | 7 | Thomas Okarma Md Executive Chairman | Funding Raised | — | 28 patents Therapeutic proteins (FSTL1) for cardiac tissue repair and heart failure treatment | — |
| 22 | Cephasonics OEM ultrasound solutions provider, empowering medical device innovation with advanced ultrasound technology | $4M | 132 mo ago | 10 | Richard Tobias CEO & President | Seed | — | — | — |
| 23 | Cytobank Cloud-based big data and analytics platform for single cell technologies | $4M | 119 mo ago | 10 | — | Acquired | — | — | — |
| 24 | MediSens Digital continence care solutions improving quality of life and caregiver efficiency | $4M | 111 mo ago | 24 | Behrooz Yadegar CEO | Series A | — | — | — |
| 25 | AIxMed AI-based 3D cytology sample analysis tools for pathologists | $3M | 37 mo ago | 17 | Samuel Chen Founder | Series A | — | 16 patents AI-driven imaging and analysis of cytopathology specimens for diagnostic enhancement | — |
| 26 | Cytorum Provider of single cell analysis services using cytometry-based platforms | $2M | 49 mo ago | — | Tom Wehrman Co-Founder & CSO | Funding Raised | — | — | — |
| 27 | Solinas Medical Vascular access technology for Hemodialysis | $2M | 153 mo ago | 4 | James Hong President & CEO | Funding Raised | — | — | — |
| 28 | SE3D Education 3D bioprinting at lab automation solutions | $1M | 117 mo ago | — | Mayasari Lim Co-Founder & CEO | Funding Raised | — | — | — |
| 29 | Chai Biotechnologies Developer of qPCR machines and diagnostics for research, agriculture, and health | $1M | — | 35 | Josh Perfetto CEO & Founder | Early Stage | — | — | — |
| 30 | HeartBeam Developer of a device for monitoring cardiac health | $200K | 82 mo ago | 15 15 → 33 (+120%) | Branislav Vajdic Chief Executive Officer And Founder | Public | Top 50M | 69 patents Wearable ECG patches and mobile three‑lead monitors for cardiac rhythm detection | 1 launch |
| 31 | Signosis Developer of bioassays for life science research | $157K | 219 mo ago | 9 | — | Funding Raised | Top 10M | — | 4 launchs |
| 32 | Engage Bio Developer of immunotherapies for the treatment of cancer | $125K | 50 mo ago | — | Kathryn Strobel Kwant Co-Founder and CSO | Acquired | — | — | — |
Top 12 Life Sciences companies in Santa Clara
#1
Series C · Santa Clara, California · founded 2009 · 37 employees$56.6Mraised▾
Shape Memory Medical is a developer of embolization devices based on Shape Memory Polymer material. The company is developing peripheral vascular and neurovascular embolization devices. SMP foams are low-density polyurethane, and their formulation and pore sizes can be modified to create materials with a wide range of different properties.
- Apr 2025Series C$17M
- Feb 2024Series C$38M
- Apr 2023Series B$4.8M
- May 2020Series B$11.5M
#2
Seed · Santa Clara, California · founded 2023$4.7Mraised▾
AI-powered solutions to enhance laboratory workflows. The company offers EI CoPilot, is an AI automation assistant that improves the speed and accuracy of data analysis, transforming traditional manual processes into automated workflows.
- Feb 2026Seed$4.7M
#3
Series D · Santa Clara, California · founded 2014 · 39 employees$124.6Mraised▾
NeuSpera is developing miniaturized injectable neuromodulation technologies. The company aims to create implantable devices to treat chronic diseases. As of 2015, NeuSpera had received regulatory approvals for 3 implantable neuromodulation devices and a 4th wearable device that provides remote monitoring of patients with epilepsy. One of these new products contains a fundamental advancement to the company’s core therapy – Closed-Loop Vagus Nerve Stimulation Therapy for epilepsy while two others enable the company to enter into two large markets – Heart Failure and Mobile Health.
- Jul 2024Series D$23M
- Jun 2021Series C$65.7M
- Jan 2018Series B$26M
- Jun 2016Series A$8.9M
#4
Acquired · Santa Clara, California · founded 2002 · 158 employees$169.5Mraised▾
Developer of a device for vascular access management. The company has two products Vascade is a fully integrated, extravascular, bioabsorbable femoral access closure system and CATALYST is designed to provide temporary hemostasis and enhance coagulation for patients.
- Jul 2020Series E$45M
- Feb 2018Conventional Debt—
- Feb 2018Series D—
- Jan 2018Series D$39.2M
#5
Public · Santa Clara, California · founded 1995 · 5968 employees$10.4Mraised▾
Developer of diversified instruments for scientific and laboratory management. It offers a range of analytical instrument and supplies for chromatography, spectroscopy, chemical standards, and others. It also provides services for the food industry, environment and forensics, pharmaceutical, diagnostics, chemical and energy, and research.
- Dec 2023Grant (prize money)$432.4K
- Dec 2022Grant (prize money)$23.6K
- Sep 2022Post IPO$606K
- Nov 2021Grant (prize money)$338.8K
#6
Acquired · Santa Clara, California · founded 2009 · 571 employees$147.5Mraised▾
Developer of cardiovascular balloon dilation catheters. It incorporates tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation thereby limiting injury to healthy tissues. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons.
- Mar 2019Post IPO$10M
- Dec 2018Series C$15M
- Oct 2017Series C$35M
- Nov 2016Series C$45M
#7
Acqui-Hired · Santa Clara, California · founded 2004 · 24 employees$148.7Mraised▾
Online slot gaming platform offering diverse games and trusted service. It is a B2C platform providing a wide array of online slot games with high RTP. The platform emphasizes fair play and offers a user-friendly experience with features like account login, free registration, and multiple deposit options. It provides access to popular slot games and aims to deliver an engaging and potentially rewarding experience for players. The platform also offers customer support and strives to create a secure and reliable environment for online gaming. It is focused on providing entertainment and opportunities for players to win through its various slot offerings.
- Jan 2016Conventional Debt$37M
- Jan 2016Series E$23M
- Jun 2014Series E$40M
- Jun 2014Venture Debt$24M
#8
Series A · Santa Clara, California · founded 2012 · 13 employees$7.5Mraised▾
Provider of a tissue imagine software and hardware solution for research diagnosis. The company provides a microscope product based on an all-fiber laser source featuring seamless integration of the laser source and the microscope unit through fiber delivery for in vivo multimodal, label-free tissue imaging applications. The imaging software developed by the company allows clinicians and doctors to diagnose patient specimens from biopsy samples. The software can be integrated with PACS.
- Mar 2023Grant (prize money)$2M
- Feb 2021Series A$3M
- Jan 2019Series A$3.5M
- Dec 2015Seed$1M
#9
Acquired · Santa Clara, California · founded 2004 · 60 employees$95Mraised▾
Developer of medical devices to treat ocular diseases. The company develops Catalys Precision Laser System is a cataract surgery system based on high-precision ablation using femtosecond laser technology. Also, it develops the PASCAL Method of retinal photocoagulation.
- Nov 2012Series E$35M
- Oct 2009Series D$30.2M
- Mar 2008Series C$16M
- Apr 2006Series B$13.8M
#10
Acquired · Santa Clara, California · founded 1999 · 156 employees$101Mraised▾
XenoPort is developing and commercializing a portfolio of internally discovered product candidates for neurological disorders. Provides treatment for Restless Leg Syndrome (RLS) and Post-Herpetic Neuralgia (PHN). Offers two products - Horizant (gabapentin enacarbil, Extended-Release Tablets approved for the USA) and Regnite (gabapentin enacarbil Extended-Release Tablets approved for Japan and marketed by Astellas Pharma). XenoPort claims to hold all other world-wide rights to gabapentin enacarbil. The pipeline includes potential treatments for patients with Parkinson’s disease (XP21279), relapsing-remitting multiple sclerosis and psoriasis (XP23829), and Alcohol Use Disorder (Arbaclofen Placabil).
#11
Series B · Santa Clara, California · founded 2005 · 900 employees$40.5Mraised▾
Contract research organization for cell culture product and animal model manufacturer. The company specializes in custom animal models and molecular biology tools. The core competencies include the generation of custom genetically-modified rodent models. The services range from DNA vector construction to embryonic stem cell manipulation and microinjection, tailor-made DNA vectors, and research-use viruses. Cyagen can construct almost any type of DNA vector using their VectorBuilder platform, which allows researchers to custom design and orders their own vector online, and manufacture research-use stem cells and related culture reagents. Cyagen boasts a comprehensive portfolio of research-use stem cell lines, including embryonic stem cells and multiple lineages of somatic stem cells derived from various species.
- Feb 2020Series B$40.5M
#12
Series B · Santa Clara, California · founded 2006 · 15 employees$20Mraised▾
Developer of an imaging system for the analysis of genes in a single cell. The company’s patented technology includes a Synthetic Aperture Optics system used for the analysis of multiple gene expressions in single cells. This technology can be used for imaging full tissue sections using laser beams at subcellular resolution. It develops Rebus Esper an integrated, automated platform that brings together advancements in imaging, fluidics, chemistry and bioinformatics to deliver spatial omics data.
- Nov 2020Series B$20M
- Sep 2009Grant (prize money)$2.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.